M. Vanhedde-drs, S. Becker, P. S. Sow, J. Presley, and M. , Aikenhead at the Bill and Melinda Gates foundation for fruitful discussions and funding, and the Gay communities in France and Canada (COQSIDA, REZO) who supported this work, Petour at Gilead Sciences for donating study drugs, and members of the Independent Data and Safety Monitoring Board for their expertise and guidance (Drs D. Costagliola (Chair), Y. Yazdanpanah, V.-K. Nguyen, A.-M. Taburet, and C. Taéron)

A. J. Blashill, P. P. Ehlinger, K. H. Mayer, and S. A. Safren, Optimizing Adherence to Preexposure and Postexposure Prophylaxis: The Need for an Integrated Biobehavioral Approach, Clinical Infectious Diseases, vol.60, issue.suppl 3, pp.187-190, 2015.
DOI : 10.1093/cid/civ111

C. Hojilla, J. Koester, K. A. Cohen, S. E. Buchbinder, S. Ladzekpo et al., Sexual behavior, risk compensation, and HIV prevention strategies among participants in the San Francisco PrEP demonstration project: A qualitative analysis of counseling notes, AIDS and Behavior. Retrieved, 2015.

M. M. Cassell, D. T. Halperin, J. D. Shelton, and D. Stanton, HIV and risk behaviour: Risk compensation: The Achilles' heel of innovations in HIV prevention?, BMJ: British Medical Journal, issue.7541, pp.332-605, 2006.

F. Cazein, J. Pillonel, L. Strat, Y. Pinget, R. et al., Découvertes de séropositivité VIH et de SIDA, Bulletin Épidémiologique Hebdomadaire, pp.9-10, 2003.

K. Choopanya, M. Martin, P. Suntharasamai, U. Sangkum, P. A. Mock et al., Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial, The Lancet, vol.381, issue.9883, pp.381-2083, 2013.
DOI : 10.1016/S0140-6736(13)61127-7

M. S. Cohen, HIV Treatment as Prevention and ???The Swiss Statement???: in for a Dime, in for a Dollar?, Clinical Infectious Diseases, vol.51, issue.11, pp.1323-1324, 2010.
DOI : 10.1086/656810

S. Team, A. L. Corneli, J. Deese, M. Wang, D. Taylor et al., Prevention of HIV-1 infection with early antiretroviral therapy Retrieved from http://doi.org/ 10 FEM-PrEP: Adherence patterns and factors associated with adherence to a daily oral study product for pre-exposure prophylaxis, The New England Journal of Medicine Journal of Acquired Immune Deficiency Syndromes, vol.365, issue.63, pp.493-505, 1056.

L. A. Eaton and S. Kalichman, Risk compensation in HIV prevention: Implications for vaccines, microbicides, and other biomedical HIV prevention technologies, Current HIV/AIDS Reports, vol.35, issue.4, pp.165-172, 2007.
DOI : 10.1097/00042560-199712010-00007

H. J. Gilmore, A. Liu, K. A. Koester, K. R. Amico, V. Mcmahan et al., Participant Experiences and Facilitators and Barriers to Pill Use Among Men Who Have Sex with Men in the iPrEx Pre-Exposure Prophylaxis Trial in San Francisco, AIDS Patient Care and STDs, vol.27, issue.10, pp.560-566, 2013.
DOI : 10.1089/apc.2013.0116

R. M. Grant, P. L. Anderson, V. Mcmahan, A. Liu, K. R. Amico et al., Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study, The Lancet Infectious Diseases, vol.14, issue.9, pp.820-829, 2014.
DOI : 10.1016/S1473-3099(14)70847-3

R. M. Grant, J. R. Lama, P. L. Anderson, V. Mcmahan, A. Y. Liu et al., Preexposure chemoprophylaxis for HIV prevention in men who have sex with men Changes in sexual risk behavior among participants in a PrEP HIV prevention trial, ? iPrEx Study Team. The New England Journal of Medicine Sexually Transmitted Diseases, vol.363, issue.2712, pp.2587-2599, 2008.

J. E. Haberer, J. M. Baeten, J. Campbell, J. Wangisi, E. Katabira et al., Adherence to Antiretroviral Prophylaxis for HIV Prevention: A Substudy Cohort within a Clinical Trial of Serodiscordant Couples in East Africa, e1001511. Retrieved from http, 2013.
DOI : 10.1371/journal.pmed.1001511.t004

M. Hogben and N. Liddon, Disinhibition and risk compensation: Scope, definitions, and perspective, Sexually Transmitted Diseases, vol.35, issue.12, pp.1009-1010, 2008.

M. L. Kamb, M. Fishbein, J. M. Douglas, F. Rhodes, J. Rogers et al., Efficacy of riskreduction counseling to prevent human immunodeficiency virus and sexually transmitted diseases: A randomized controlled trial. Project RESPECT Study Group, JAMA, issue.13, pp.280-1161, 1998.

A. Y. Liu, E. Vittinghoff, K. Chillag, K. Mayer, M. Thompson et al., Sexual Risk Behavior Among HIV-Uninfected Men Who Have Sex With Men Participating in a Tenofovir Preexposure Prophylaxis Randomized Trial in the United States, e81997. Retrieved from http, pp.87-94, 2013.
DOI : 10.1097/QAI.0b013e31828f097a

S. Mccormack, D. T. Dunn, M. Desai, D. I. Dolling, M. Gafos et al., Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial, The Lancet, vol.387, issue.10013, pp.140-67300056, 2015.
DOI : 10.1016/S0140-6736(15)00056-2

A. Tangmunkongvorakul, S. Chariyalertsak, K. R. Amico, P. Saokhieo, V. Wannalak et al., Retrieved from http://doi. org/10 Facilitators and barriers to medication adherence in an HIV prevention study among men who have sex with men in the iPrEx study in Chiang Mai, Medicine AIDS Care, vol.373, issue.238, pp.2237-2246, 1056.

K. Underhill, Study designs for identifying risk compensation behavior among users of biomedical HIV prevention technologies: Balancing methodological rigor and??research ethics, Social Science & Medicine, vol.94, pp.115-123, 2013.
DOI : 10.1016/j.socscimed.2013.03.020

L. Van-damme, A. Corneli, K. Ahmed, K. Agot, J. Lombaard et al., Preexposure Prophylaxis for HIV Infection among African Women, New England Journal of Medicine, vol.367, issue.5, pp.411-422, 2012.
DOI : 10.1056/NEJMoa1202614

J. E. Volk, J. L. Marcus, T. Phengrasamy, D. Blechinger, D. P. Nguyen et al., No New HIV Infections With Increasing Use of HIV Preexposure Prophylaxis in a Clinical Practice Setting: Figure 1., Clinical Infectious Diseases, vol.61, issue.10, 2015.
DOI : 10.1093/cid/civ778